William A. Hawkins
William A. Hawkins's purchase track record
William A. Hawkins has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/24/2023 | BVS | $236K | +54.3% | +49.2% | +10.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Transaction History
| MDXG | ▲ Buy | Grant | 50,913 | $185K | 6/10/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 1,505 | $0 | 6/9/2026 | View on chart |
| BVS | ▲ Buy | Option Exercise | 39,789 | $0 | 6/2/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 28,609 | $185K | 6/18/2025 | View on chart |
| BIIB | ▲ Buy | Grant | 2,370 | $0 | 6/17/2025 | View on chart |
| BVS | ▲ Buy | Option Exercise | 26,493 | $0 | 6/2/2025 | View on chart |
| BIIB | ▲ Buy | Grant | 1,340 | $0 | 6/21/2024 | View on chart |
| BVS | ▲ Buy | Option Exercise | 30,400 | $0 | 6/7/2024 | View on chart |
| MDXG | ▲ Buy | Grant | 23,190 | $168K | 6/5/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 960 | $0 | 6/26/2023 | View on chart |
| MDXG | ▲ Buy | Grant | 35,354 | $175K | 6/13/2023 | View on chart |
| BVS | ▲ Buy | Option Exercise | 16,648 | $0 | 6/6/2023 | View on chart |
| BVS | ▲ Buy | Open Market | 44,000 | $117K | 5/25/2023 | View on chart |
| BVS | ▲ Buy | Open Market | 44,000 | $118K | 5/24/2023 | View on chart |
| BVS | ▲ Buy | Option Exercise | 3,949 | — | 3/14/2023 | View on chart |
| BIIB | ▲ Buy | Grant | 1,370 | $0 | 6/15/2022 | View on chart |
| MDXG | ▲ Buy | Grant | 44,191 | $175K | 6/7/2022 | View on chart |
| BVS | ▲ Buy | Option Exercise | 40,573 | — | 4/1/2022 | View on chart |
| BVS | ▲ Buy | Option Exercise | 13,500 | — | 2/11/2022 | View on chart |
| BVS | ▲ Buy | Option Exercise | 38,288 | — | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification
A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.